Medtronic infusion set recall
This article was originally published in The Gray Sheet
Executive Summary
Medtronic is recalling specific lots of its Quick-set infusion set used with the MiniMed Paradigm insulin pumps; the set is a replaceable plastic tube that delivers insulin from the pump to the diabetes patient. Medtronic recently discovered that about 2% of the sets in a lot of about 60,000 may not allow the pump to vent air properly, which could cause the device to deliver the wrong amount of insulin. Medtronic is advising patients to check 1www.medtronicdiabetes.com to see which box numbers are being recalled. The company will replace the affected products for free. Medtronic estimates about 3 million Quick-set sets are currently with customers
You may also be interested in...
Regulatory News In Brief
Pandemic flu test: FDA granted emergency use authorization July 24 to a third diagnostic test for detecting the HINI pandemic flu virus, Quest Diagnostics Focus Diagnostics Influenza H1N1 (2009) real-time reverse transcription polymerase chain reaction test. The authorization, enabled by the 2004 Project BioShield law, permits Quest to distribute the test to clinical labs from its California-based Focus Diagnostics subsidiary. The assay can amplify viral genetic material obtained from nose or throat swabs, or nasal discharges, in patients with symptoms of respiratory infection. The previous two EUA tests were developed by the federal government
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.